TEAM
PIPELINE
Retinitis Pigmentosa
Duchenne muscular dystrophy
Amyotrophic lateral sclerosis
Myotonic dystrophy type I
Alzheimer’s disease
TECHNOLOGY
INTELLECTUAL PROPERTY
COLLABORATIONS
INVESTORS & COLLABORATORS
CONTACT
info@miramoonpharma.com
TEAM
PIPELINE
Retinitis Pigmentosa
Duchenne muscular dystrophy
Amyotrophic lateral sclerosis
Myotonic dystrophy type I
Alzheimer’s disease
TECHNOLOGY
INTELLECTUAL PROPERTY
COLLABORATIONS
INVESTORS & COLLABORATORS
CONTACT
TEAM
PIPELINE
Retinitis Pigmentosa
Duchenne muscular dystrophy
Amyotrophic lateral sclerosis
Myotonic dystrophy type I
Alzheimer’s disease
TECHNOLOGY
INTELLECTUAL PROPERTY
COLLABORATIONS
INVESTORS & COLLABORATORS
CONTACT
UPV-EHU
UPV-EHU
18 de March de 2021
by
admin-sgs
0 Comments
UPV-EHU
READ MORE
X
This website uses cookies to remember users and understand ways to enhance their experience.
More info
Refuse
Accept
Privacidad
